EUVIMEDEUVIMED entdecken
Crossref

Auto‐Deactivation of BODIPY‐Derived Type I Photosensitizer Post Photodynamic Therapy under Hypoxia

Xia Wang, Zhaobin Wang, He Hang, Fude Feng iD

ChemBioChem · 2025-02 · 26 (3)

DOI: 10.1002/cbic.202400767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 28.11.2024. Verfasst von Xia Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of High Performance Polymer Material and Technology of Ministry of Education, Department of Polymer Science & Engineering, School …. Hauptthemen laut MEDLINE: Boron Compounds, Photosensitizing Agents, Photochemotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The long‐lasting activity of photosensitizers during photodynamic therapy (PDT) causes excessive damage and arouses great concerns about biosafety. Herein, we synthesized a pyridinium‐decorated diiodo‐BODIPY compound (PyBDP) and investigated its photosensitizing activity under hypoxic condition in the presence of NADH that is abundant in the mitochondria of hypoxic tumors. The unique property of PyBDP lies in the redox environment‐dependent photo‐response. At green light exposure, PyBDP is converted into a colorless inactive form by interacting with NADH in a two‐step one‐electron transfer process. Interestingly, the NADH‐dependent hydrogenation of PyBDP is affected by the presence of cytochrome c (Cyt c ox ) that is an important component of mitochondrial electron transport chain (Mito‐ETC), unless Cyt c ox is exhausted. Active radical species is produced during the photocatalytic reaction, which adds the understanding of PyBDP‐induced photodamage. Therefore, we applied the strategy of auto‐deactivation PDT using a BODIPY photosensitizer by tethering triphenylphosphonium to PyBDP. After PDT effect in a type I pathway, the photosensitizer underwent almost entire auto‐deactivation in hypoxic HeLa cells. This work paves a way for the development of reductive PDT with enhanced safety and efficacy in fighting hypoxic tumors independent on reactive oxygen species (ROS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsPhotosensitizing AgentsPhotochemotherapyHumansHeLa CellsNADCell SurvivalMolecular Structure

Stichwörter der Autor:innen

Auto-deactivationBODIPYHypoxia-tolerant photodynamic therapyIn-cell photoredox catalysisNADH

Substanzen

Boron CompoundsPhotosensitizing Agents4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneNAD

Autor:innen und Institutionen

  • MOE Key Laboratory of High Performance Polymer Material and Technology of Ministry of Education, Department of Polymer Science & Engineering, School of Chemistry & Chemical Engineering, Nanjing University, Jiangsu, Nanj…

ORCID-Profile: Fude Feng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, X., Wang, Z., Hang, H., & Feng, F. (2025). Auto‐Deactivation of BODIPY‐Derived Type I Photosensitizer Post Photodynamic Therapy under Hypoxia. ChemBioChem, 26(3). https://doi.org/10.1002/cbic.202400767

Vancouver

Wang X, Wang Z, Hang H, Feng F. Auto‐Deactivation of BODIPY‐Derived Type I Photosensitizer Post Photodynamic Therapy under Hypoxia. ChemBioChem. 2025;26(3). doi:10.1002/cbic.202400767

BibTeX
@article{Wang2025,
  author = {Wang, Xia and Wang, Zhaobin and Hang, He and Feng, Fude},
  title = {Auto‐Deactivation of BODIPY‐Derived Type I Photosensitizer Post Photodynamic Therapy under Hypoxia},
  journal = {ChemBioChem},
  year = {2025},
  volume = {26},
  number = {3},
  doi = {10.1002/cbic.202400767}
}
Kostenlos starten →